Palisade Bio Inc (PALI) - Total Liabilities
Based on the latest financial reports, Palisade Bio Inc (PALI) has total liabilities worth $3.76 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Palisade Bio Inc (PALI) cash flow conversion to assess how effectively this company generates cash.
Palisade Bio Inc - Total Liabilities Trend (2005–2024)
This chart illustrates how Palisade Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Check Palisade Bio Inc (PALI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Palisade Bio Inc Competitors by Total Liabilities
The table below lists competitors of Palisade Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inozyme Pharma Inc
NASDAQ:INZY
|
USA | $63.37 Million |
|
PLINTAS
KLSE:5320
|
Malaysia | RM3.02 Billion |
|
Thye Ming Industrial Co Ltd
TW:9927
|
Taiwan | NT$1.13 Billion |
|
MM Forgings Limited
NSE:MMFL
|
India | Rs15.56 Billion |
|
Mayur Uniquoters Ltd
NSE:MAYURUNIQ
|
India | Rs1.16 Billion |
|
Webzen Inc
KQ:069080
|
Korea | ₩77.66 Billion |
|
Tukas Gida Sanayi ve Ticaret AS
IS:TUKAS
|
Turkey | TL9.42 Billion |
|
Forafric Global PLC Ordinary Shares
NASDAQ:AFRI
|
USA | $240.76 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Palisade Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Palisade Bio Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Palisade Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Palisade Bio Inc (2005–2024)
The table below shows the annual total liabilities of Palisade Bio Inc from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.39 Million | +23.69% |
| 2023-12-31 | $2.74 Million | -16.60% |
| 2022-12-31 | $3.28 Million | -36.20% |
| 2021-12-31 | $5.15 Million | -49.13% |
| 2020-12-31 | $10.12 Million | +594.01% |
| 2019-12-31 | $1.46 Million | -10.83% |
| 2018-12-31 | $1.63 Million | -69.55% |
| 2017-12-31 | $5.37 Million | -52.37% |
| 2016-12-31 | $11.27 Million | +12.94% |
| 2015-12-31 | $9.98 Million | -17.67% |
| 2014-12-31 | $12.12 Million | +10.27% |
| 2013-12-31 | $11.00 Million | +518.60% |
| 2012-12-31 | $1.78 Million | -26.74% |
| 2011-12-31 | $2.43 Million | -11.35% |
| 2010-12-31 | $2.74 Million | -65.88% |
| 2009-12-31 | $8.02 Million | +533.97% |
| 2008-12-31 | $1.27 Million | +24.47% |
| 2007-12-31 | $1.02 Million | +167.30% |
| 2006-12-31 | $380.36K | -63.07% |
| 2005-12-31 | $1.03 Million | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the… Read more